Explore
Companies
Investors
Top 50
Streams
Trending tech news
Latest investments
Latest acquisitions
Products
Automate
Trackers
Innovation Services
About Index
Index
By TNW
Log in
Register
AVROBIO
3231
AVROBIO
Technology
Biotechnology
Clinical stage company developing step-change cell and gene therapies targeting cancer and rare disease.
Suggest edits
Raised
$184.7M
Follow us
Also headquartered in Boston
General Electric
DraftKings
Sophia
Bain Capital
TA Associates
Wikibon
DataRobot
Zipcar
State Street
Battery Ventures
Companies in the same industry
Cernostics
InVivo Therapeutics
Pressure BioSciences
Scholar Rock
MannKind Corporation
Cepheid
Immune Design
CRISPR Therapeutics
AngioScore
AIT Bioscience
Alexa global traffic share
Twitter followers
Overview
Funding
3
Add info
Add round
21 Jun
2018
$99,700,000
IPO
VC-backed Avrobio rolls out IPO
PE HUB
01 Feb
2018
$60,000,000
Venture capital (Series B)
Atlas Venture
,
Aisling Capital
,
Clarus Ventures
,
+12
Avrobio Raises $60M in Series B Financing
FinSMEs
+2
02 Aug
2016
$25,000,000
Venture capital (Series A)
Atlas Venture
,
SV Life Sciences
,
Clarus
AVROBIO, Inc. Announces $25 Million Series A Financing to Advance Novel, Clinical-Stage Gene Therapies for Rare Diseases and Cancer | Business Wire
businesswire
